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Heart failure (HF) is a complex clinical syndrome affecting 1-2% of the adult population.1 It 
places a heavy burden on both patients and their families which often increases in the later 
stages of the illness yet studies to date have not focused on the complexity of advanced 
disease.2  Indeed, the definition of ‘advanced HF’ is still debated in both clinician and patient 
communities.3 
Research priorities have traditionally been set by researchers and funders but involving 
those directly affected by the condition in the process can lead to more valid, credible and 
relevant research findings.4 We want to set the research agenda for advanced HF by 
undertaking a prioritisation exercise involving patients, carers and frontline clinicians.  
The James Lind Alliance (JLA) is a non-profit making initiative which aims to identify 
unanswered research questions by facilitating Priority Setting Partnerships, or PSPs, to 
engage with those most affected by a particular condition.5 The Universities of Oxford, 
Bristol and Cambridge have been working collaboratively, under the guidance of the JLA, to 
establish the advanced HF PSP. A steering group of 16 people directly affected by advanced 
HF including patients, carers and clinicians are overseeing the project.  
The steering group have defined the scope of the PSP as there is no universally agreed 
definition of ‘advanced HF’ amongst professional groups. Cardiologists and HF nurse 
specialists may recognise ‘advanced’ as patients requiring tertiary referral for consideration 
of devices or transplantation whilst generalists, such as geriatricians or general 
practitioners, may consider ‘advanced’ HF in those patients with significant and progressive 
symptoms, and in the context of frailty, multimorbidity and polypharmacy. For the purposes 
of the PSP, patients with advanced HF are ‘people who know they have HF, may have had it 
for some time and find their condition has a significant impact on their life. They may need 
to take a lot of medication, or have needed hospital admission because of their HF, but are 
not currently in hospital’. 
An online survey has been designed to ask patients, carers and frontline clinicians what they 
think the priorities for advanced HF research should be. The survey, which launches in May 
2018, asks what research is needed on the impact of HF on physical health, emotion 
wellbeing and the treatment and support provided to people with advanced HF.  
The members of the steering group will promote the survey through their wider partner 
networks, which include patient groups and healthcare clinics, and through relevant 
websites such as HF charities and local NHS trusts. A review of the literature will be carried 
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out to identify where priorities have already been addressed, and where research gaps exist. 
Priorities will then be sorted to generate a shorter list for discussion at a final workshop in 
early 2019 where a ‘Top 10’ priority list will be agreed. The priorities will be disseminated 
widely to researchers and funders to ensure this project has the maximum impact on the 
advanced HF research agenda. 
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